The unique transfusion needs of a hematopoietic stem cell transplant (HSCT) patient require collaboration between the Clinical Transplant and Transfusion Medicine services. Successful interaction is essential to the optimal management of HSCT patients with the goals of reducing the risk of alloimmunization, infection transmission, and avoiding potential medical errors.
KeywordsHematopoietic Stem Cell Transplant Hematopoietic Stem Cell Transplant Patient Stem Cell Product Unit PRBC Bone Marrow Product
- Gajewski, J., Petz, L., Calhoun, L., et. al. (1992). Hemolysis of transfused group O red blood cells in minor ABO-incompatible unrelated-donor bone marrow transplants in patients receiving cyclosporine without posttransplant methotrexate. Blood, 79:3076–3085.Google Scholar
- Lapierre, V., Mahé, C., Aupérin, A., et. al. (2005). Platelet transfusion containing ABO-incompatible plasma and hepatic veno-occlusive disease after hematopoietic transplantation in young children. Transplant, 80:314–319.Google Scholar
- Nevo, S., Fuller, A., Zahurak, M., Hartley, E., Borinsky, M., Volgesang, G. (2007). Profound thrombocytopenia and survival of hematopoietic stem cell transplant patients without clinically significant bleeding, using prophylactic platelet transfusion triggers of 10 × 109 or 20 × 109/L. Transfusion, 49:1700–1709.Google Scholar
- Petz LD. (1987). Immunohematologic problems associated with bone marrow transplantation. Transfusion Med Rev, 1:85–100.Google Scholar
- Worel, N., Grenix, H., Keil, F., et al. (2002). Severe immune hemolysis after minor ABO-mismatched allogeneic peripheral blood progenitor cell transplantation occurs more frequently after nonmyeloablative than myeloablative conditioning. Transfusion, 42:1293–1301.Google Scholar